Flash interviews with the ICTHIC Conference Chairmen
Benjamin Brenner: As the chairman of the conference, what do you think are the main goals of the ICTHIC Congress? What...
ARCHIVE
How to improve patient’s awareness about the risk of cancer-associated thrombosis
Although patients with cancer have a four-to-five-fold increased risk of venous thromboembolism (VTE) compared with the...
Interview with the ICTHIC Magazine Editor-In-Chief
Anna Falanga: What are the main purposes of the conference and how does this event impact the value of the magazine?...
PODCAST. Thrombosis and coagulation in the contemporary management of breast cancer. Waiting for ICTHIC 2022
Breast cancer is the most commonly diagnosed cancer in women accounting for a quarter of cancer cases worldwide. This...
Prediction of disease progression and mortality in patients with metastatic gastrointestinal cancer: the role of thrombin generation and D-dimer
Gastrointestinal (GI) cancers represent 26% of the global cancer incidence and more than one-third of all...
Thrombosis management in hematological cancers vs solid tumors: what are the differences?
During the ICTHIC webinar “CAT management: challenges in different cancer populations,” Prof Darko Antic...
Management and safety considerations in specific sub-populations of patients with cancer
During the ICTHIC webinar “CAT management: challenges in different cancer populations”, Prof Walter Ageno gave a...
11th International Conference on Thrombosis and Hemostasis Issues in Cancer
It’s almost time for the 11th International Conference on Thrombosis and Hemostasis Issues in Cancer. It will be...
The role of neutrophils in cancer and thrombosis. Waiting for ICTHIC 2022
The role of neutrophils in innate immunity is well known, but only recently they have been linked to other phenomena...
Low-dose apixaban as secondary prophylaxis in patients with cancer: is it safe?
Recurrent venous thromboembolism (VTE) and major bleeding are the two major challenges in managing cancer-associated...